Amgen’s EU approval of Imdylltra strengthens its lung‑cancer pipeline, suggesting a potential upside breakout. Technical patterns show the stock trading above its 50‑day SMA, reinforcing a bullish bias.

The market welcomed Amgen’s EU nod, nudging sentiment toward a mild bullish tilt amidst broader healthcare rally. Support remains solid as volatility has stayed below the 20‑day ATR, indicating healthy momentum.

While EU approval boosts short‑term prospects, long‑term success hinges on competitive landscape and reimbursement challenges. Thus, a cautious stance with neutral bias remains appropriate.

Data indicates Imdylltra’s launch aligns with a rising on‑balance‑sheet momentum, reflected in a 1.3× ROC ranking for the quarter. Additionally, the 70‑level moving average crossover supports a bullish signal.